Description
CHS-114 (also known as Tagmokitug) is an investigational medication currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is being tested in Phase 1 trials to determine its safety and potential effectiveness when given alone or in combination with other treatments like toripalimab (an immunotherapy drug) and standard chemotherapy regimens (like 5-Fluorouracil and Cisplatin). These trials are in the early stages, primarily focused on assessing safety and finding the right dose. The trials are looking at patients with specific characteristics, such as those with BRAF mutations, EGFR mutations, HER2-negative status, microsatellite instability-stable (MSS) tumors, certain levels of PD-L1 expression, and VEGF mutations. The goal is to see if CHS-114 can help control or shrink tumors in these patients.
Mechanism of Action
CHS-114 is being investigated as a potential treatment for advanced solid tumors. The specific way it works (its mechanism of action) is still being studied in clinical trials. It is designed to interact with the body's systems in a way that might target cancer cells or influence the tumor environment. Researchers are evaluating how CHS-114 affects tumor growth and the body's response to it.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.